IDEAYA Biosciences, Inc. (IDYA) Form 10-Q — Nov 3, 2026
IDEAYA Biosciences reported Q3 2026 results with a net loss of $125.7 million ($1.22 per share), as R&D spending rose to $121.6 million, and a nine-month net loss of $336.7 million versus $30.4 million a year earlier. The company completed its darovasertib NDA submission to the FDA for metastatic uveal melanoma under the Real-Time Oncology Review program in the third quarter. The company ended the quarter with approximately $1.15 billion in cash and marketable securities, bolstered by a $345.0 million gross follow-on offering in June 2026 and $32.9 million in ATM sales, which it says funds operations for at least twelve months.
Key figures
- Revenue
- 25660000
- Revenue Yoy
- -88%
- Total Assets
- 1216020000
- Cash Position
- 1150000000
- Shares Outstanding
- 96694575
- Runway
- at least 12 months from filing date
- Q3 revenue
- 10242000
- Q3 rnd expense
- 121576000
- Atm remaining capacity
- 122600000
- Follow on net proceeds
- 323400000
- Nine month rnd expense
- 325991000
- Follow on gross proceeds
- 345000000
- Servier remaining performance obligations
- 139789000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.